1.Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082. Related Tags: buy Bemarituzumab | purchase Bemarituzumab | Bemarituzumab cost | order Bemarituzum...
目前,Bemarituzumab尚未在国内获得批准上市,仅处于临床试验阶段。在2020年5月,该药物已经在美国开始了Phase 3的临床试验,试验将对比Bemarituzumab和安慰剂对HER2阳性晚期胃癌患者的疗效。同时,该药物也在其他一些国家的临床试验中进行评估。 虽然Bemarituzumab在国内尚未获得上市许可,但随着临床试验的进展,这种药物在未...
In the phase 2 FIGHT study (Wainberg, 2021; Catenacci, 2021), bemarituzumab + mFOLFOX6 improved progression-free survival (PFS; HR, 0.68; 95% CI, 0.441.04; p = 0.07) and led to a 5.7 month longer median overall survival (OS; 19.2 months vs 13.5 months; HR, 0.60; 95% CI, ...
在2020年5月,该药物已经在美国开始了Phase 3的临床试验,试验将对比Bemarituzumab和安慰剂对HER2阳性晚期胃癌患者的疗效。同时,该药物也在其他一些国家的临床试验中进行评估。虽然Bemarituzumab在国内尚未获得上市许可,但随着临床试验的进展,这种药物在未来可能成为HER2阳性胃癌治疗的一种新选择。因此,对于HER2阳性胃癌...
[3] Kang Y K, Kang W K, Shin D B, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized Phase III noninferiority trial. Ann Oncol, ...
3)次要终点ORR方面,bemarituzumab组与安慰剂组相比大幅提高(ORR:46.8% vs 33.3%)。 安全性方面,所有级别的不良事件发生率在bemarituzumab组和安慰剂组相似(分别为100%和98.7%)。角膜事件在bemarituzumab组更常见(67.1% vs 10.4%),其中...
“With these data in hand, we plan to continue to collaborate with regulatory agencies on next steps, initiate a global phase 3 trial in gastric cancer, and begin studying bemarituzumab in other epithelial cancers that overexpress FGFR2b.” REFERENCE Ph...
[3]Trastuzumabderuxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: adose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827-836. [4]PD-1 Blockade inTumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun25;372(26):2509-20. ...
Background We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2+/3+membranous s...
The dose-limiting toxicity (DLT) period is 28 days; observed safety data will influence additional enrollment to Part 1, de-escalation of bemarituzumab, or the recommended phase 3 dose (RP3D). For Part 1, primary endpoints are DLTs and adverse events; secondary endpoints include OS, PFS, ...